Interim Position Statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults)
Following data from the REMAP-CAP trial, this position statement provides information to clinicians and healthcare organisations considering prescribing tocilizumab for COVID-19 pneumonia when the internal governance arrangements are in place.
Source:
Chief Medical Officer
SPS commentary:
Eligibility criteria under this position statement are:
Dosing and administration:
A therapeutic alert detailing steps organisations should take to implement this position statement has also been produced in conjunction.